Skip to main content
Publications
Aparicio J, Virgili Manrique AC, Capdevila J, Munoz Boza F, Galvan P, Richart P, Oliveres H, Paez D, Hernando J, Serrano S, Vera R, Hernandez‑Yague X, Gallego RA, Riesco‑Martinez MC, Garcia de Albeniz Martinez X , Maurel J. Randomized phase II trial of FOLFIRI‑panitumumab compared with FOLFIRI alone in patients with RAS wild‑type circulating tumor DNA metastatic colorectal cancer beyond progression to first‑line FOLFOX‑panitumumab: the BEYOND study (GEMCAD 17‑01) . Clin Trans Oncol. 2022 Nov;24(11):2155-65. doi: 10.1007/s12094-022-02868-x
Trickey A, Nixon E, Christensen H, Finn A, Thomas A, Relton C, Montgomery C, Hemani G, Metz J, Walker JG, Turner K, Kwiatkowska R, Sauchelli S , Danon L, Brooks-Pollock E. University students and staff able to maintain low daily contact numbers during various COVID-19 guideline periods . Epidemiol Infect. 2021 Aug 10;149:e169. doi: 10.1017/S0950268821001618
Cheol Lee J, Hung JY, Kim YC, Chang GC, Soo Yoo S, Yang SH, Davis KL , Nagar SP , Taylor A, Yong Lee S, Shih JY. Real-world treatment patterns in patients with EGFR mutation-positive NSCLC receiving a first line, first- or second-generation EGFR tyrosine kinase inhibitor in South Korea and Taiwan . Asian Pac J Cancer Bio. 2021 May 20;6(2). doi: 10.31557/APJCB.2021.6.2.123-132